Molecular characterisation of group A streptococcus isolates recovered from the north-west of Pretoria, South Africa.


Journal

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
ISSN: 2078-5135
Titre abrégé: S Afr Med J
Pays: South Africa
ID NLM: 0404520

Informations de publication

Date de publication:
30 Apr 2021
Historique:
received: 30 04 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 22 12 2021
Statut: epublish

Résumé

Group A streptococcus (GAS) is a human pathogen responsible for a wide range of invasive and non-invasive infections. Pharyngitis caused by GAS may have complications such as acute rheumatic fever subsequently leading to rheumatic heart disease (RHD). RHD continues to have high morbidity and mortality and affects millions of children and young adults, mostly in developing countries. An effective preventive vaccine against GAS may reduce the morbidity and mortality. A 30-valent M-protein-based vaccine is currently at the clinical trials stage of development. Potential vaccine coverage will depend on the geographical distribution of GAS emm (M protein) types. To determine the emm types of GAS isolates circulating in the north-west of Pretoria, South Africa. Throat swabs were collected from patients aged 3 - 20 years presenting with pharyngitis at one local clinic. In addition, GAS clinical isolates were collected from the National Health Laboratory Service diagnostic laboratory. Emm genotyping was done on the GAS isolates by amplification of the emm gene followed by sequencing of the 5' portion of the gene. The emm types were correlated with the types in the vaccine. A total of 54 GAS isolates were collected, comprising 19 pharyngitis and 35 clinical isolates. We found 15 different emm types among the 43 GAS isolates that were successfully sequenced. Eleven isolates (20%) could not be typed. The most prevalent emm type was 92 (26%), which is part of the 30-valent vaccine. This was followed by emm 25 and 75, each accounting for 12% of the isolates. Up to 67% of the emm types are not covered in the 30-valent vaccine. Fifteen emm types were identified, of which 92 was the most prevalent. It is concerning that 67% of the emm types are not covered in the vaccine currently under development. It is recommended that surveillance studies be extended to include other parts of the country in order to expand knowledge of the circulating emm types.

Sections du résumé

BACKGROUND BACKGROUND
Group A streptococcus (GAS) is a human pathogen responsible for a wide range of invasive and non-invasive infections. Pharyngitis caused by GAS may have complications such as acute rheumatic fever subsequently leading to rheumatic heart disease (RHD). RHD continues to have high morbidity and mortality and affects millions of children and young adults, mostly in developing countries. An effective preventive vaccine against GAS may reduce the morbidity and mortality. A 30-valent M-protein-based vaccine is currently at the clinical trials stage of development. Potential vaccine coverage will depend on the geographical distribution of GAS emm (M protein) types.
OBJECTIVES OBJECTIVE
To determine the emm types of GAS isolates circulating in the north-west of Pretoria, South Africa.
METHODS METHODS
Throat swabs were collected from patients aged 3 - 20 years presenting with pharyngitis at one local clinic. In addition, GAS clinical isolates were collected from the National Health Laboratory Service diagnostic laboratory. Emm genotyping was done on the GAS isolates by amplification of the emm gene followed by sequencing of the 5' portion of the gene. The emm types were correlated with the types in the vaccine.
RESULTS RESULTS
A total of 54 GAS isolates were collected, comprising 19 pharyngitis and 35 clinical isolates. We found 15 different emm types among the 43 GAS isolates that were successfully sequenced. Eleven isolates (20%) could not be typed. The most prevalent emm type was 92 (26%), which is part of the 30-valent vaccine. This was followed by emm 25 and 75, each accounting for 12% of the isolates. Up to 67% of the emm types are not covered in the 30-valent vaccine.
CONCLUSIONS CONCLUSIONS
Fifteen emm types were identified, of which 92 was the most prevalent. It is concerning that 67% of the emm types are not covered in the vaccine currently under development. It is recommended that surveillance studies be extended to include other parts of the country in order to expand knowledge of the circulating emm types.

Identifiants

pubmed: 34852893
doi: 10.7196/SAMJ.2021.v111i5.14613
doi:

Substances chimiques

Streptococcal Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-490

Commentaires et corrections

Type : ErratumIn

Auteurs

X V Khosa (XV)

Department of Microbiology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa. xongeekay@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH